Quay,
"...including gene therapies which have the potential to cure the condition."
Gene Therapy ain't curing DMD anytime soon.
Read the Sarepta and Pfizer releases from last couple of years to get the full picture...or the analyst reports on Antisense website.
Safety concerns...and lack of efficacy are big issues.
FDA has placed a hold on Pfizer's GT program in the US due to safety issues.
Treatments that are pursuing additional dystrophin are not showing efficacy.
Not many sleeps until EMA approval.
.
- Forums
- ASX - By Stock
- PER
- Ann: Positive feedback received on Paediatric Investigation Plan
Ann: Positive feedback received on Paediatric Investigation Plan, page-94
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.8¢ |
Change
0.003(4.00%) |
Mkt cap ! $70.32M |
Open | High | Low | Value | Volume |
7.8¢ | 7.8¢ | 7.8¢ | $312 | 4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 230 | 7.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.9¢ | 120000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 230 | 0.075 |
2 | 312990 | 0.073 |
3 | 322000 | 0.072 |
1 | 20000 | 0.071 |
3 | 349887 | 0.070 |
Price($) | Vol. | No. |
---|---|---|
0.079 | 120000 | 1 |
0.080 | 102781 | 2 |
0.081 | 26315 | 1 |
0.085 | 250000 | 2 |
0.086 | 6000 | 1 |
Last trade - 10.08am 14/05/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |